FDA INTER-CENTER LABELING COMMITTEE ON ADVERSE REACTIONS ESTABLISHED
This article was originally published in The Tan Sheet
Executive Summary
FDA INTER-CENTER LABELING COMMITTEE ON ADVERSE REACTIONS ESTABLISHED to work on making adverse drug reaction labeling more user-friendly. The inter-center labeling committee was formed by FDA in response to reports from physicians of inconsistencies encountered in the adverse events section of drug labeling. The committee has representatives from the Center for Drug Evaluation & Research, Center for Biologics Evaluation & Research and the Center for Devices & Radiological Health.